Marksans Pharma board recommends dividend

Marksans Pharma Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524404 | NSE: MARKSANS

31 May 2022 Evaluate

Marksans Pharma has informed that the Board of Directors of the Company at its meeting held on May 30, 2022, has recommended final dividend at Re 0.25 (Rupee Zero and Paise Twenty Five), 25% per equity share of Re 1 each face value for the financial year ended March 31, 2022, subject to approval of the shareholders in the ensuing Annual General Meeting.

The above information is a part of company’s filings submitted to BSE.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.50
Dr. Reddys Labs.	1202.80
Cipla	1397.20
Lupin	2090.00
Zydus Lifesciences	1202.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.